Recht, M <br/><br/>
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.  [electronic resource] 

 -  Haemophilia : the official journal of the World Federation of Hemophilia  Jul 2009 
 - 869-80 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2516 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2516.2009.02027.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Bayes Theorem<br/>Blood Coagulation Factor Inhibitors--genetics<br/>Child<br/>Factor VIII--genetics<br/>Hemophilia A--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>Peptide Fragments--genetics<br/>Treatment Outcome<br/>Young Adult